by Truveta Research | Jun 6, 2023 | Research, Research Insights
Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...
by Truveta staff | May 25, 2023 | Research
Every 40 seconds, someone in the United States has a stroke. Every 3 minutes and 14 seconds, someone dies from a stroke. The fifth leading cause of death in the US and a leading cause of adult disability, 7.8 million adults have experienced a stroke in their lifetime....
by Truveta Research | May 19, 2023 | Research
Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Peter D. Smits, PhD ⊕Truveta, Inc, Bellevue, WA,Sarah Stewart, MD ⊕Truveta, Inc, Bellevue, WA, Patricia D. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc,...
by Truveta Research | May 9, 2023 | Research, Research Insights
This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes. Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease...
by Truveta Research | May 5, 2023 | Research
Authors: Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Michael D. Wang, MD ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Sarah Stewart, MD ⊕Truveta, Inc, Bellevue, WA, Christopher M. Worsham, MD MPH ⊕Department...
by Truveta Research | Apr 30, 2023 | Research, Research Insights
Since the 1990s, the negative impact of prescription opioids – particularly death from overdose – have become an epidemic in the US (Centers for Disease Control and Prevention, 2022; Paulozzi et al., 2011). More recently, in the early 2010s, the US embarked on a new...
